Literature DB >> 12523667

Formation of fine drug particles by cogrinding with cyclodextrins. I. The use of beta-cyclodextrin anhydrate and hydrate.

Arpansiree Wongmekiat1, Yuichi Tozuka, Toshio Oguchi, Keiji Yamamoto.   

Abstract

PURPOSE: To improve the micromeritical properties of pranlukast (PRK) hydrate, a cogrinding process with cyclodextrin was used, and the formation of fine drug particles was investigated.
METHODS: PRK crystals were ground with either beta-cyclodextrin (beta-CD) anhydrate or beta-CD hydrate crystals at a mixing molar ratio of 2:1 (beta-CD:PRK) to prepare the ground mixtures (GMs). Powder X-ray diffraction measurement and particle size analysis were performed.
RESULTS: The two GMs differed from one another in appearance, wettability, and fine particle production. Quantitative determination demonstrated that when the beta-CD hydrate/PRK GM was dispersed in water, 96% of PRK loaded in GM became fine particles smaller than 0.8 microm. In contrast, only 1.4% of PRK in GM transformed to fine particles in the case of beta-CD anhydrate/PRK GM. The PRK fine particles were considered to be dispersed as small crystals. The stability of PRK particles in the aqueous solution was improved by the addition of a water-soluble polymer.
CONCLUSION: Cogrinding with a beta-CD of higher water content can be an effective method to prepare fine drug particles at the submicron level.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12523667     DOI: 10.1023/a:1021401826554

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

1.  Study of tolbutamide-hydroxypropyl-gamma-cyclodextrin interaction in solution and solid state.

Authors:  M D Veiga; F Ahsan
Journal:  Chem Pharm Bull (Tokyo)       Date:  2000-06       Impact factor: 1.645

2.  Some important considerations in the use of cyclodextrins.

Authors:  J Blanchard; S Proniuk
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

3.  Mechanistic studies on hydrotropic solubilization of nifedipine in nicotinamide solution.

Authors:  H Suzuki; H Sunada
Journal:  Chem Pharm Bull (Tokyo)       Date:  1998-01       Impact factor: 1.645

4.  Improvement of dissolution rate and oral bioavailability of a sparingly water-soluble drug, (+/-)-5-[[2-(2-naphthalenylmethyl)-5-benzoxazolyl]-methyl]- 2, 4-thiazolidinedione, in co-ground mixture with D-mannitol.

Authors:  H Kubo; M Mizobe
Journal:  Biol Pharm Bull       Date:  1997-04       Impact factor: 2.233

Review 5.  Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.

Authors:  T Loftsson; M E Brewster
Journal:  J Pharm Sci       Date:  1996-10       Impact factor: 3.534

6.  Improvement of the in vitro dissolution of praziquantel by complexation with alpha-, beta- and gamma-cyclodextrins.

Authors:  G Becket; L J Schep; M Y Tan
Journal:  Int J Pharm       Date:  1999-03-01       Impact factor: 5.875

7.  Properties of solid dispersions of piroxicam in polyvinylpyrrolidone.

Authors:  V Tantishaiyakul; N Kaewnopparat; S Ingkatawornwong
Journal:  Int J Pharm       Date:  1999-04-30       Impact factor: 5.875

8.  Effect of grinding with hydroxypropyl cellulose on the dissolution and particle size of a poorly water-soluble drug.

Authors:  T Yamada; N Saito; T Imai; M Otagiri
Journal:  Chem Pharm Bull (Tokyo)       Date:  1999-09       Impact factor: 1.645

9.  Fluorometric study of the molecular states of 2,5-diphenyloxazole in ground mixtures with gamma-cyclodextrin.

Authors:  K Yamamoto; T Oguchi; E Yonemochi; Y Matsumura; Y Nakai
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

10.  Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region.

Authors:  N Kondo; T Iwao; H Masuda; K Yamanouchi; Y Ishihara; N Yamada; T Haga; Y Ogawa; K Yokoyama
Journal:  Chem Pharm Bull (Tokyo)       Date:  1993-04       Impact factor: 1.645

View more
  8 in total

1.  Biophysical Studies and In Vitro Effects of Tumor Cell Lines of Cannabidiol and Its Cyclodextrin Inclusion Complexes.

Authors:  Kyriaki Hatziagapiou; Kostas Bethanis; Eleni Koniari; Elias Christoforides; Olti Nikola; Athena Andreou; Aimilia Mantzou; George P Chrousos; Christina Kanaka-Gantenbein; George I Lambrou
Journal:  Pharmaceutics       Date:  2022-03-26       Impact factor: 6.525

2.  Danazol-beta-cyclodextrin binary system: a potential application in emergency contraception by the oral route.

Authors:  Ganesh S Jadhav; Pradeep R Vavia; Tarala D Nandedkar
Journal:  AAPS PharmSciTech       Date:  2007-05-11       Impact factor: 3.246

3.  Nanosuspension: An approach to enhance solubility of drugs.

Authors:  Vishal R Patel; Y K Agrawal
Journal:  J Adv Pharm Technol Res       Date:  2011-04

4.  Role of Cyclodextrins and Drug Solid State Properties on Flufenamic Acid Dissolution Performance from Tablets.

Authors:  Francesca Maestrelli; Marzia Cirri; Enrico De Luca; Diletta Biagi; Paola Mura
Journal:  Pharmaceutics       Date:  2022-01-26       Impact factor: 6.321

5.  Hydroxypropyl-β-cyclodextrin Enhances Oral Absorption of Silymarin Nanoparticles Prepared Using PureNano™ Continuous Crystallizer.

Authors:  Risako Onodera; Tomohiro Hayashi; Keiichi Motoyama; Kohei Tahara; Hirofumi Takeuchi
Journal:  Pharmaceutics       Date:  2022-02-10       Impact factor: 6.321

6.  Improving dissolution and oral bioavailability of pranlukast hemihydrate by particle surface modification with surfactants and homogenization.

Authors:  Eun-Sol Ha; In-hwan Baek; Jin-Wook Yoo; Yunjin Jung; Min-Soo Kim
Journal:  Drug Des Devel Ther       Date:  2015-06-24       Impact factor: 4.162

Review 7.  Grinding as Solvent-Free Green Chemistry Approach for Cyclodextrin Inclusion Complex Preparation in the Solid State.

Authors:  Mario Jug; Paola Angela Mura
Journal:  Pharmaceutics       Date:  2018-10-16       Impact factor: 6.321

Review 8.  Emerging role of nanosuspensions in drug delivery systems.

Authors:  Shery Jacob; Anroop B Nair; Jigar Shah
Journal:  Biomater Res       Date:  2020-01-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.